FRI0430 IXEKIZUMAB IMPROVES THE SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS REGARDLESS OF SEX, DURATION OF DISEASE, OR BODY MASS INDEX IN TWO RANDOMIZED, PHASE 3 CLINICAL TRIALS

Background Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A. During 24 weeks (wks) of treatment, IXE resulted in significantly greater improvements versus placebo (PBO) in the signs and symptoms of active psoriatic arthritis (PsA) in two randomized Phase 3 studies.1,2 Objectives To evaluate the consistency of clinical response with IXE in demographic subsets of patients (pts) with active PsA. Methods Clinical response to IXE was analyzed from an integrated database of 2 randomized, double-blind, Phase 3 studies in biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)-naive (SPIRIT-P1) pts or in pts with prior inadequate response or intolerance to TNF inhibitors (SPIRIT-P2). Analyses were conducted on subgroups defined by sex, body mass index (BMI), and duration of disease ( Results Response rates at Wk 24 (Table) were significantly (p Conclusion IXE was superior to PBO in the treatment of pts with active PsA at Wk 24 regardless of sex or disease duration, as well as in normal, overweight, and obese BMI subgroups. References [1] Mease, et al. Ann Rheum Dis. 2017 [2] Nash, et al. Lancet. 2017 Disclosure of Interests Lihi Eder Grant/research support from: AbbVie, Eli Lilly and Company, Amgen, Celgene, UCB, Janssen, Novartis, and Pfizer, Consultant for: AbbVie, Eli Lilly and Company, Amgen, Celgene, UCB, Janssen, Novartis, and Pfizer, Satish Odhav Grant/research support from: AbbVie, Ardea Biosciences, AstraZeneca, BMS, Celgene Corporation, Centocor, Eli Lilly and Company, Galapagos, Genentech, GSK, Human Genome Sciences, Janssen, Merck, Mesoblast, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Takeda Pharmaceuticals, UCB, and Vertex Pharmaceuticals, Consultant for: AbbVie, Ardea Biosciences, AstraZeneca, BMS, Celgene Corporation, Centocor, Eli Lilly and Company, Galapagos, Genentech, GSK, Human Genome Sciences, Janssen, Merck, Mesoblast, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Takeda Pharmaceuticals, UCB, and Vertex Pharmaceuticals, Speakers bureau: AbbVie, Ardea Biosciences, AstraZeneca, BMS, Celgene Corporation, Centocor, Eli Lilly and Company, Galapagos, Genentech, GSK, Human Genome Sciences, Janssen, Merck, Mesoblast, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Takeda Pharmaceuticals, UCB, and Vertex Pharmaceuticals, Mariusz Korkosz Consultant for: Eli Lilly and Company, Novartis, Roche, MSD, UCB, and AbbVie, Speakers bureau: Eli Lilly and Company, Novartis, Roche, MSD, UCB, and AbbVie, Aubrey Trevelin Sprabery Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Amanda M. Gellett Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Chen-Yen Lin Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, So Young Park Employee of: Eli Lilly and Company, Clinton C Bertram Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Alexis Ogdie Grant/research support from: (To my university) Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Grant/research support from: Novartis, Pfizer, Consultant for: AbbVie, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly and Company, Novartis, Pfizer, and Takeda, Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly, Novartis, Pfizer Inc, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda, Consultant for: Abbvie, Amgen, BMS, Celgene, Corrona, Lilly, Novartis, Pfizer, Takeda